Principal efficacy results The trial achieved
its primary efficacy endpoint of demonstrating a reduction in one or more of these key biomarkers.
Renal denervation failed to achieve
the primary efficacy endpoint of a decrease in systolic blood pressure measured in the doctor's office from baseline to six months or the powered secondary efficacy endpoint of decrease in average 24 - hour levels by ambulatory blood pressure monitoring, which provides more reliable readings.
Of the 1,952 patients randomised in ION - 1, ION - 2 and ION - 3, 1,886 patients (96.6 %) achieved
the primary efficacy endpoint of SVR12.